-2%
Duotide (Vilanterol Trifenatate+Umeclidinium Bromide) is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).
Each Dry Powder Inhaler capsule contains:
- Vilanterol 25 micrograms (as Vilanterol Trifenatate INN)
- Umeclidinium 62.5 micrograms (as Umeclidinium Bromide INN)
Duotide is an inhalation powder containing a combination of Umeclidinium, an anticholinergic agent, and Vilanterol, a long-acting beta₂-agonist (LABA), administered via inhalation.
The pharmacological effects of beta₂-adrenergic agonists such as vilanterol are attributed to stimulation of intracellular adenyl cyclase, an enzyme that converts adenosine triphosphate (ATP) into cyclic 3’,5’-adenosine monophosphate (cAMP). Increased cAMP levels cause relaxation of bronchial smooth muscle and inhibit the release of mediators of immediate hypersensitivity, particularly from mast cells.
Umeclidinium is a long-acting muscarinic antagonist (LAMA), commonly referred to as an anticholinergic. It exhibits similar activity across muscarinic receptor subtypes M₁ to M₅. It works by blocking M₃ receptors in airway smooth muscle, resulting in bronchodilation.